{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:10:46Z","timestamp":1793139046417,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1001\/jamaoncol.2021.0039","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T16:31:50Z","timestamp":1615480310000},"page":"700","source":"Crossref","is-referenced-by-count":70,"title":["Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Carlo","family":"Greco","sequence":"first","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Pares","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Pimentel","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Louro","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Santiago","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vieira","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Stroom","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Mateus","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Soares","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Marques","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Freitas","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a","family":"Coelho","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Seixas","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Fuks","sequence":"additional","affiliation":[{"name":"The Champalimaud Centre for the Unknown, Lisbon, Portugal"},{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi210002r1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1053\/j.seminoncol.2019.08.001","article-title":"The evolving role of external beam radiotherapy in localized prostate cancer.","volume":"46","author":"Greco","year":"2019","journal-title":"Semin Oncol"},{"issue":"9","key":"coi210002r2","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: a ten-year analysis.","volume":"9","author":"Katz","year":"2017","journal-title":"Cureus"},{"issue":"4","key":"coi210002r3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies.","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"coi210002r4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology.","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"coi210002r5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrurol.2016.106","article-title":"Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?","volume":"13","author":"Arcangeli","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"1","key":"coi210002r6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.prro.2017.08.004","article-title":"A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.","volume":"8","author":"Jackson","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"coi210002r7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20471","article-title":"Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States.","volume":"3","author":"Mahase","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10196","key":"coi210002r8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"coi210002r9","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi210002r10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.semradonc.2017.02.006","article-title":"Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer.","volume":"27","author":"Kishan","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"coi210002r11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials.","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"issue":"3","key":"coi210002r12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"key":"coi210002r13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014results from a multi-institutional clinical trial.","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi210002r14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijrobp.2013.05.019","article-title":"The non-Gaussian nature of prostate motion based on real-time intrafraction tracking.","volume":"87","author":"Lin","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"coi210002r15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1046\/j.1365-2168.2000.01542.x","article-title":"Anatomy of Denonvilliers\u2019 fascia and pelvic nerves, impotence, and implications for the colorectal surgeon.","volume":"87","author":"Lindsey","year":"2000","journal-title":"Br J Surg"},{"issue":"2","key":"coi210002r16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0360-3016(02)03008-0","article-title":"Measurement of intrafractional prostate motion using magnetic resonance imaging.","volume":"54","author":"Mah","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi210002r17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2020.01.029","article-title":"Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: results from a phase II study.","volume":"146","author":"Greco","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"coi210002r18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/1533034616649495","article-title":"Interfraction anatomical variability can lead to significantly increased rectal dose for patients undergoing stereotactic body radiotherapy for prostate cancer.","volume":"16","author":"Wahl","year":"2017","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"coi210002r19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"issue":"3","key":"coi210002r20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results.","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"coi210002r21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy.","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi210002r22","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.ijrobp.2019.06.492","article-title":"High dose-rate prostate brachytherapy as monotherapy: a single fraction may not be enough.","volume":"105","author":"Morton","year":"2019","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"coi210002r23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1172\/JCI97631","article-title":"Single-dose radiotherapy disables tumor cell homologous recombination via ischemia\/reperfusion injury.","volume":"129","author":"Bodo","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"coi210002r24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ijrobp.2019.02.033","article-title":"Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy.","volume":"104","author":"Greco","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi210002r25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/(ISSN)1097-0142","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"issue":"20","key":"coi210002r26","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data.","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"issue":"1","key":"coi210002r27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form.","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"issue":"1","key":"coi210002r28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.urology.2012.09.016","article-title":"Stratification of postprostatectomy urinary function using expanded prostate cancer index composite.","volume":"81","author":"Ellison","year":"2013","journal-title":"Urology"},{"issue":"1","key":"coi210002r29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.juro.2007.08.136","article-title":"Long-term urinary sequelae following 125iodine prostate brachytherapy.","volume":"179","author":"Crook","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"coi210002r30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi210002r31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13014-018-1112-0","article-title":"ONE SHOT\u2014single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I\/II trial.","volume":"13","author":"Zilli","year":"2018","journal-title":"Radiat Oncol"},{"issue":"11","key":"coi210002r32","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S1470-2045(19)30652-7","article-title":"Stereotactic beam radiotherapy for prostate cancer: is less, more?","volume":"20","author":"Miralbell","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi210002r33","article-title":"Prostate specific antigen five years following stereotactic body radiation therapy (SBRT) for low and intermediate risk prostate cancer: an ablative procedure?","volume":"35","author":"Kataria","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi210002r34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijrobp.2018.05.072","article-title":"The future of artificial intelligence in radiation oncology.","volume":"102","author":"Thompson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi210002r35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijrobp.2020.08.017","article-title":"Conformal avoidance of normal organs at risk by perfusion-modulated dose sculpting in tumor single-dose radiation therapy.","volume":"109","author":"Greco","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi210002r36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.urology.2017.11.016","article-title":"Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data.","volume":"115","author":"Karsh","year":"2018","journal-title":"Urology"},{"issue":"15","key":"coi210002r37","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer.","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"coi210002r38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"issue":"5","key":"coi210002r39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"May","key":"coi210002r40","first-page":"122","article-title":"Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.","volume":"4","author":"Woo","year":"2014","journal-title":"Front Oncol"},{"issue":"4","key":"coi210002r41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000447222","article-title":"Comparison of late urinary symptoms following SBRT and SBRT with IMRT supplementation for prostate cancer.","volume":"11","author":"Feng","year":"2018","journal-title":"Curr Urol"},{"issue":"30","key":"coi210002r42","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2014.56.6547","article-title":"Late urinary symptom flare after prostate stereotactic body radiation therapy.","volume":"32","author":"Collins","year":"2014","journal-title":"J Clin Oncol"},{"issue":"30","key":"coi210002r43","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1200\/JCO.2014.56.5572","article-title":"Regarding relative toxicities of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer.","volume":"32","author":"Fuller","year":"2014","journal-title":"J Clin Oncol"},{"issue":"October","key":"coi210002r44","first-page":"290","article-title":"Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.","volume":"4","author":"Rana","year":"2014","journal-title":"Front Oncol"},{"issue":"8","key":"coi210002r45","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/0284186X.2017.1299221","article-title":"Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.","volume":"56","author":"Repka","year":"2017","journal-title":"Acta Oncol"},{"issue":"1","key":"coi210002r46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"issue":"20","key":"coi210002r47","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1200\/JCO.2016.67.3764","article-title":"Making radiation therapy for prostate cancer more economical and more convenient.","volume":"34","author":"Zietman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi210002r48","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1200\/JCO.2014.55.2380","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis.","volume":"32","author":"D\u2019Amico","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2777068\/jamaoncology_greco_2021_oi_210002_1621004991.49549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:36:23Z","timestamp":1698017783000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2777068"}},"subtitle":["Results From the PROSINT Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}